Datroway Recommended for Approval in EU as Targeted Breast Cancer Treatment

Datroway Receives Recommendation for Approval in the European Union

AstraZeneca and Daiichi Sankyo's Datroway, a promising breast cancer treatment, has received a recommendation for approval in the European Union. This follows its previous approvals in the U.S. and Japan, marking a significant step forward for the drug's availability.

Datroway is specifically designed for patients with a type of breast cancer that has spread or cannot be surgically removed, and whose cancer cells possess a specific genetic signature. The treatment combines a tumor-killing drug with an antibody that targets cancerous tissue, offering a targeted approach to fighting the disease.

While Datroway's application for treating lung cancer was withdrawn in the EU due to mixed results from clinical trials, the companies remain optimistic about its potential in treating certain types of breast and lung cancers. Datroway is part of a group of drugs that AstraZeneca expects to generate peak annual sales of at least $5 billion, contributing to the company's goal of reaching $80 billion in annual revenue by the end of the decade.